Investigating a new treatment approach for aggressive brain cancer.
A Phase 1 Adaptive Dose Escalation Study of Mycophenolate Mofetil in Combination with Temozolomide for Patients with Newly Diagnosed Glioblastoma
This study is looking at how a combination of two medications, mycophenolate mofetil and temozolomide, can help improve treatment for people who have just been diagnosed with glioblastoma, a tough type of brain tumor, by finding the best doses to help fight the cancer and improve survival.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10898610 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma, a highly aggressive brain tumor with poor survival rates. It aims to explore the combination of mycophenolate mofetil and temozolomide to improve treatment outcomes for newly diagnosed patients. The study will adaptively escalate doses to find the most effective treatment regimen while monitoring patient responses. By targeting the unique metabolic needs of cancer cells, the research seeks to reduce tumor recurrence and enhance patient survival.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have been newly diagnosed with glioblastoma and are seeking innovative treatment options.
Not a fit: Patients with advanced glioblastoma who have already undergone multiple lines of treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and longer survival for patients with glioblastoma.
How similar studies have performed: While the combination of mycophenolate mofetil and temozolomide is being explored, similar approaches in targeting cancer metabolism have shown promise in other studies.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Ahmed, Atique U. — Northwestern University at Chicago
- Study coordinator: Ahmed, Atique U.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.